2-Bromopalmitate inhibits malignant behaviors of HPSCC cells by hindering the membrane location of Ras protein
- PMID: 38159074
- PMCID: PMC10903252
- DOI: 10.1177/15353702231220671
2-Bromopalmitate inhibits malignant behaviors of HPSCC cells by hindering the membrane location of Ras protein
Abstract
Palmitoylation, which is mediated by protein acyltransferase (PAT) and performs important biological functions, is the only reversible lipid modification in organism. To study the effect of protein palmitoylation on hypopharyngeal squamous cell carcinoma (HPSCC), the expression levels of 23 PATs in tumor tissues of 8 HPSCC patients were determined, and high mRNA and protein levels of DHHC9 and DHHC15 were found. Subsequently, we investigated the effect of 2-bromopalmitate (2BP), a small-molecular inhibitor of protein palmitoylation, on the behavior of Fadu cells in vitro (50 μM) and in nude mouse xenograft models (50 μmol/kg), and found that 2BP suppressed the proliferation, invasion, and migration of Fadu cells without increasing cell apoptosis. Mechanistically, the effect of 2BP on the transduction of BMP, Wnt, Shh, and FGF signaling pathways was tested with qRT-PCR, and its drug target was explored with western blotting and acyl-biotinyl exchange assay. Our results showed that 2BP inhibited the transduction of the FGF/ERK signaling pathway. The palmitoylation level of Ras protein decreased after 2BP treatment, and its distribution in the cell membrane structure was reduced significantly. The findings of this work reveal that protein palmitoylation mediated by DHHC9 and DHHC15 may play important roles in the occurrence and development of HPSCC. 2BP is able to inhibit the malignant biological behaviors of HPSCC cells, possibly via hindering the palmitoylation and membrane location of Ras protein, which might, in turn, offer a low-toxicity anti-cancer drug for targeting the treatment of HPSCC.
Keywords: 2-Bromopalmitate; FGF/ERK signaling pathway; Ras protein; hypopharyngeal squamous cell carcinoma; malignant behaviors; protein palmitoylation.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures







Similar articles
-
TMEM184B promotes proliferation, migration and invasion, and inhibits apoptosis in hypopharyngeal squamous cell carcinoma.J Cell Mol Med. 2022 Nov;26(21):5551-5561. doi: 10.1111/jcmm.17572. Epub 2022 Oct 18. J Cell Mol Med. 2022. PMID: 36254814 Free PMC article.
-
2-Bromopalmitate impairs neural stem/progenitor cell proliferation, promotes cell apoptosis and induces malformation in zebrafish embryonic brain.Neurotoxicol Teratol. 2015 Jul-Aug;50:53-63. doi: 10.1016/j.ntt.2015.06.001. Epub 2015 Jun 6. Neurotoxicol Teratol. 2015. PMID: 26056731
-
Profiling targets of the irreversible palmitoylation inhibitor 2-bromopalmitate.ACS Chem Biol. 2013 Sep 20;8(9):1912-7. doi: 10.1021/cb400380s. Epub 2013 Jul 25. ACS Chem Biol. 2013. PMID: 23844586 Free PMC article.
-
Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.Anticancer Res. 2021 Aug;41(8):3789-3799. doi: 10.21873/anticanres.15171. Anticancer Res. 2021. PMID: 34281838
-
Palmitoylation as a Signal for Delivery.Adv Exp Med Biol. 2020;1248:399-424. doi: 10.1007/978-981-15-3266-5_16. Adv Exp Med Biol. 2020. PMID: 32185719 Review.
Cited by
-
Protein palmitoylation: biological functions, disease, and therapeutic targets.MedComm (2020). 2025 Feb 21;6(3):e70096. doi: 10.1002/mco2.70096. eCollection 2025 Mar. MedComm (2020). 2025. PMID: 39991624 Free PMC article. Review.
-
Neural-Inflammation Mechanism of Spinal Palmitic Acid Promoting Atopic Dermatitis in Mice.J Inflamm Res. 2025 Jun 17;18:7907-7919. doi: 10.2147/JIR.S525663. eCollection 2025. J Inflamm Res. 2025. PMID: 40546406 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous